Journal article
Modelling ischemia-reperfusion injury (IRI) in vitro using metabolically matured induced pluripotent stem cell-derived cardiomyocytes
A Hidalgo, N Glass, D Ovchinnikov, SK Yang, X Zhang, S Mazzone, C Chen, E Wolvetang, J Cooper-White
APL Bioengineering | AIP Publishing | Published : 2018
DOI: 10.1063/1.5000746
Abstract
Coronary intervention following ST-segment elevation myocardial infarction (STEMI) is the treatment of choice for reducing cardiomyocyte death but paradoxically leads to reperfusion injury. Pharmacological post-conditioning is an attractive approach to minimize Ischemia-Reperfusion Injury (IRI), but candidate drugs identified in IRI animal models have performed poorly in human clinical trials, highlighting the need for a human cell-based model of IRI. In this work, we show that when we imposed sequential hypoxia and reoxygenation episodes [mimicking the ischemia (I) and reperfusion (R) events] to immature human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs), they display significant..
View full abstractGrants
Awarded by Australian Research Council Special Research Initiative Scheme
Funding Acknowledgements
The authors would like to acknowledge funding from the Australian Research Council Special Research Initiative Scheme (SR110001002). This work was performed in part at the Queensland node of the Australian National Fabrication Facility (ANFF-Q), a company established under the National Collaborative Research Infrastructure Strategy to provide nano- and microfabrication facilities for Australia's researchers.